Cargando…

Association of Antiphospholipid Antibodies with Clinical Manifestations in Children with Systemic Lupus Erythematosus

Background: The aim of the study is to evaluate the effect of the presence of antiphospholipid antibodies on the clinical and laboratory manifestations, disease activity and outcomes of the disease in patients with childhood-onset systemic lupus erythematosus (cSLE). Methods: We conducted a 10-year...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrovic, Gordana, Pasic, Srdjan, Soldatovic, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967991/
https://www.ncbi.nlm.nih.gov/pubmed/36835956
http://dx.doi.org/10.3390/jcm12041424
_version_ 1784897403301658624
author Petrovic, Gordana
Pasic, Srdjan
Soldatovic, Ivan
author_facet Petrovic, Gordana
Pasic, Srdjan
Soldatovic, Ivan
author_sort Petrovic, Gordana
collection PubMed
description Background: The aim of the study is to evaluate the effect of the presence of antiphospholipid antibodies on the clinical and laboratory manifestations, disease activity and outcomes of the disease in patients with childhood-onset systemic lupus erythematosus (cSLE). Methods: We conducted a 10-year cross-sectional study with a retrospective analysis of clinical and laboratory parameters and outcome of the disease (kidney, nervous system involvement, thrombosis). For the purpose of the study, patients were divided into cohort groups based on the presence of antiphospholipid antibodies (aPLA), named the aPLA positive group, or their absence, named the aPLA negative group. Values of aPLA were defined in reference laboratories. The disease activity was measured by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, whereas tissue damage degree was measured by Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index (SLICC/ACR DI; SDI; DI). Results: Research in our center showed that patients with cSLE often had hematological, cutaneous, and non-thrombotic neurological manifestations. Antiphospholipid antibodies may be present transiently or permanently. A significant change in the titer value was observed in the IgG isotype of aCLA. The presence of higher values of IgM β2GP1 at the beginning indicates that higher disease activity can be expected. Higher disease activity correlates with greater tissue damage. Additionally, it has been shown that aPLA positive patients have two and a half times higher risk of tissue damage than aPLA negative ones. Conclusion: Our study shows that the presence of antiphospholipid antibodies in patients with childhood onset systemic lupus erythematosus may indicate a higher risk of tissue damage, but since it is a rare disease in childhood, prospective and multicenter studies are necessary to assess the importance of the presence of these antibodies.
format Online
Article
Text
id pubmed-9967991
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99679912023-02-27 Association of Antiphospholipid Antibodies with Clinical Manifestations in Children with Systemic Lupus Erythematosus Petrovic, Gordana Pasic, Srdjan Soldatovic, Ivan J Clin Med Brief Report Background: The aim of the study is to evaluate the effect of the presence of antiphospholipid antibodies on the clinical and laboratory manifestations, disease activity and outcomes of the disease in patients with childhood-onset systemic lupus erythematosus (cSLE). Methods: We conducted a 10-year cross-sectional study with a retrospective analysis of clinical and laboratory parameters and outcome of the disease (kidney, nervous system involvement, thrombosis). For the purpose of the study, patients were divided into cohort groups based on the presence of antiphospholipid antibodies (aPLA), named the aPLA positive group, or their absence, named the aPLA negative group. Values of aPLA were defined in reference laboratories. The disease activity was measured by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, whereas tissue damage degree was measured by Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index (SLICC/ACR DI; SDI; DI). Results: Research in our center showed that patients with cSLE often had hematological, cutaneous, and non-thrombotic neurological manifestations. Antiphospholipid antibodies may be present transiently or permanently. A significant change in the titer value was observed in the IgG isotype of aCLA. The presence of higher values of IgM β2GP1 at the beginning indicates that higher disease activity can be expected. Higher disease activity correlates with greater tissue damage. Additionally, it has been shown that aPLA positive patients have two and a half times higher risk of tissue damage than aPLA negative ones. Conclusion: Our study shows that the presence of antiphospholipid antibodies in patients with childhood onset systemic lupus erythematosus may indicate a higher risk of tissue damage, but since it is a rare disease in childhood, prospective and multicenter studies are necessary to assess the importance of the presence of these antibodies. MDPI 2023-02-10 /pmc/articles/PMC9967991/ /pubmed/36835956 http://dx.doi.org/10.3390/jcm12041424 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Petrovic, Gordana
Pasic, Srdjan
Soldatovic, Ivan
Association of Antiphospholipid Antibodies with Clinical Manifestations in Children with Systemic Lupus Erythematosus
title Association of Antiphospholipid Antibodies with Clinical Manifestations in Children with Systemic Lupus Erythematosus
title_full Association of Antiphospholipid Antibodies with Clinical Manifestations in Children with Systemic Lupus Erythematosus
title_fullStr Association of Antiphospholipid Antibodies with Clinical Manifestations in Children with Systemic Lupus Erythematosus
title_full_unstemmed Association of Antiphospholipid Antibodies with Clinical Manifestations in Children with Systemic Lupus Erythematosus
title_short Association of Antiphospholipid Antibodies with Clinical Manifestations in Children with Systemic Lupus Erythematosus
title_sort association of antiphospholipid antibodies with clinical manifestations in children with systemic lupus erythematosus
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967991/
https://www.ncbi.nlm.nih.gov/pubmed/36835956
http://dx.doi.org/10.3390/jcm12041424
work_keys_str_mv AT petrovicgordana associationofantiphospholipidantibodieswithclinicalmanifestationsinchildrenwithsystemiclupuserythematosus
AT pasicsrdjan associationofantiphospholipidantibodieswithclinicalmanifestationsinchildrenwithsystemiclupuserythematosus
AT soldatovicivan associationofantiphospholipidantibodieswithclinicalmanifestationsinchildrenwithsystemiclupuserythematosus